About
Urogen Pharma Ltd (NASDAQ:URGN) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 8 2026
UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer
Mar 30 2026
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
Mar 13 2026
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
Mar 2 2026
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
Mar 2 2026
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
Financials
Revenue
$109.79 M
Market Cap
$916.2 M
EPS
-3.19
Translate